Keyword: Spravato (esketamine)
NICE rejected Spravato over cost concerns and a lack of head-to-head clinical data against other NICE-recommended alternatives.
We may be focusing on our forecasts for the year ahead with today's issue, but here's some Friday news we thought you shouldn't miss.
Painted as the follow-up drug to Humira, AbbVie’s JAK med Rinvoq has blockbuster hopes in mind. An early nod in the EU could help it reach that goal.
Johnson & Johnson has faced payer pushback for its controversial antidepressive Spravato. Could new data in high-risk patients help its cause?
Despite unconventional support from President Donald Trump, Johnson & Johnson’s Spravato didn’t win broad backing at the VA.
Spravato, a tweaked form of the “party drug” ketamine, has been hailed as the first effective new treatment for major depression to have been approved in a long time, and it carries high expectations from developer Johnson & Johnson.
ICER has ruled that neither Novartis' $88,500 MS drug Mayzent nor J&J's $32,400 depression spray Spravato is cost effective.
Days after ICER called out Spravato for being too costly, developer J&J unveiled its own analysis based on a cost-per-remitter model, arguing the opposite.
Patients with treatment-resistant depression have a new option in J&J's Spravato, but the cost watchdogs at ICER say it's not cost-effective.
J&J just won approval for the first novel depression drug in years: Spravato, a tweaked version of the anesthesia medication—and street drug—ketamine.